Ftse Mib
33.683,16
1,39%
DAX
18.254,18
1,03%
S&P 500
5.473,17
-0,25%
NASDAQ
17.721,59
-0,79%
Bitcoin
64.935,87
-0,06%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Alto Neuroscience Inc (ANRO) Alto Neuroscience Inc (ANRO) Notizie

ANRO

Alto Neuroscience (ANRO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:ANRO
DataOraFonteTitoloSimboloCompagnia
20/06/202414:05Business WireAlto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with SchizophreniaNYSE:ANROAlto Neuroscience Inc
18/06/202414:05Business WireAmit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award WinnerNYSE:ANROAlto Neuroscience Inc
29/05/202414:05Business WireAlto Neuroscience to Present at the Jefferies Global Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
21/05/202414:29Edgar (US Regulatory)Form 8-K - Current reportNYSE:ANROAlto Neuroscience Inc
21/05/202414:05Business WireAlto Neuroscience Appoints Michael Hanley as Chief Operating OfficerNYSE:ANROAlto Neuroscience Inc
14/05/202422:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ANROAlto Neuroscience Inc
14/05/202422:03Business WireAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
09/05/202414:05Business WireAlto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesNYSE:ANROAlto Neuroscience Inc
23/04/202414:05Business WireAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaNYSE:ANROAlto Neuroscience Inc
03/04/202414:05Business WireAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderNYSE:ANROAlto Neuroscience Inc
21/03/202421:05Business WireAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
11/03/202413:05Business WireAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsNYSE:ANROAlto Neuroscience Inc
07/03/202414:00Business WireAlto Neuroscience to Participate in Upcoming Investor ConferencesNYSE:ANROAlto Neuroscience Inc
27/02/202414:00Business WireAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
06/02/202422:05Business WireAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNYSE:ANROAlto Neuroscience Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:ANRO

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
TEN
Tenaris
BIT
PRY
Prysmian
BIT
SRG
Snam
BIT
MONC
Moncler
BIT
LDO
Leonardo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network